MedPath
HSA Approval

INTAXEL INJECTION 6 mg/ml

SIN13180P

INTAXEL INJECTION 6 mg/ml

INTAXEL INJECTION 6 mg/ml

February 6, 2006

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFRESENIUS KABI (SINGAPORE) PTE LTD
Licence HolderFRESENIUS KABI (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION, CONCENTRATE

INTRAVENOUS

Medical Information

L01CD01

paclitaxel

Manufacturer Information

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI ONCOLOGY LIMITED

Fresenius Kabi Oncology Limited (Baddi II)

Active Ingredients

PACLITAXEL

6.0 mg/ml

Paclitaxel

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

INTAXEL INJECTION 6 mg/ml - HSA Approval | MedPath